Skip to main content
main-content

17.08.2017 | PRECLINICAL STUDIES | Ausgabe 1/2018

Investigational New Drugs 1/2018

CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance

Zeitschrift:
Investigational New Drugs > Ausgabe 1/2018
Autoren:
Kenneth K. W. To, Li-wu Fu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s10637-017-0501-9) contains supplementary material, which is available to authorized users.

Summary

Platinum (Pt)-based anticancer drugs are the mainstay of treatment for solid cancers. However, resistance to Pt drugs develops rapidly, which can be caused by overexpression of multidrug resistance transporters and activation of DNA repair. CUDC-907 is a potent molecular targeted anticancer agent, rationally designed to simultaneously inhibit histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). We investigated the potentiation effect of CUDC-907 on Pt drugs in resistant cancer cells. ABCC2 stably-transfected HEK293 cells and two pairs of parental and Pt-resistant cancer cell lines were used to test for the circumvention of resistance by CUDC-907. Chemosensitivity was assessed by the sulphorhodamine B assay. Drug combinations were evaluated by the median effect analysis. ABCC2 transport activity was examined by flow cytometric assay. Cellular Pt drug accumulation and DNA platination were detected by inductively coupled plasma optical emission spectroscopy. ABCC2, ERCC1 and p21 expression were evaluated by quantitative real-time PCR. Cell cycle analysis and apoptosis assay were performed by standard flow cytometric method. The combination of CUDC-907 with cisplatin were found to exhibit synergistic cytotoxic effect in cisplatin-resistant cancer cells. In Pt-resistant cancer cells, CUDC-907 apparently circumvented the resistance through inhibition of ABCC2 and DNA repair but induction of cell cycle arrest. In the presence of CUDC-907, cellular accumulation of Pt drugs and formation of DNA-Pt adducts were found to be increased whereas expression levels of ABCC2 and ERCC1 was inhibited in Pt-resistant cells. The data advocates further development of CUDC-907 as a resistance reversal agent for use in combination cancer chemotherapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Zusatzmaterial
Supplementary Fig. 1 CUDC-907 sensitized cisplatin-resistant HKESC-1 cisR cells to apoptosis. (A) Cells were exposed to cisplatin alone (5 μM), CUDC-907 alone (20 nM), or their combination for 48 h before harvest for apoptosis assay. A representative set of data from three independent experiments is shown. (B) Summary of apoptosis assay data in (A) from three independent experiments. Data are presented in histogram as means ± SD. (TIFF 157 kb)
10637_2017_501_MOESM1_ESM.tif
Supplementary Fig. 2 CUDC-907 increased cellular accumulation of cisplatin in cisplatin-resistant HKESC-1 cisR cells by downregulating ABCC2 expression. (Top panel) Cisplatin accumulation in CUDC-907-treated HKESC-1 and HKESC-1 cisR cells. There was a remarkable reduction in cisplatin accumulation in HKESC-1 cisR cells, relative to the parental HKESC-1 cells. (Bottom panel) Quantitative real-time PCR analysis of ABCC2 mRNA expression in CUDC-907 treated HKESC-1 and HKESC-1 cisR cells. The value in HKESC-1 cells without CUDC-907 treatment was set as 1 for comparison. The mean value from three independent experiments is shown. * p < 0.05, ** p < 0.01, compared with untreated HKESC-1 cisR cells. (TIFF 81 kb)
10637_2017_501_MOESM2_ESM.tif
Supplementary Fig. 3 CUDC-907 increased DNA platination in cisplatin-treated HKESC-1 cisR cells by downregulating ERCC1 expression. (Top panel) DNA platination in HKESC-1 and HKESC-1 cisR cells treated with combination of cisplatin (100 μM) and different concentrations of CUDC-907. There was a significant decrease in DNA platination in cisplatin-resistant HKESC-1 cisR cells, relative to the parental HKESC-1 cells. (Bottom panel) Quantitative real-time PCR analysis of ERCC1 expression in CUDC-907-treated HKESC-1 and HKESC-1 cisR cells. The value in HKESC-1 without CUDC-907 treatment was set as 1 for comparison. The mean value from three independent experiments is shown. * p < 0.05, ** p < 0.01, compared with untreated HKESC-1 cisR cells. (TIFF 80 kb)
10637_2017_501_MOESM3_ESM.tif
Supplementary Fig. 4 Cell cycle analysis in parental HKESC-1 and cisplatin-resistant HKESC-1 cisR cells after cisplatin or CUDC-907 alone or their combination. Summary of cell cycle analysis results from three independent experiments. Data are presented in histograms as mean ± SD; * p < 0.01, versus no treatment in cisplatin-resistant HKESC-1 cisR cells. (TIFF 72 kb)
10637_2017_501_MOESM4_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Investigational New Drugs 1/2018 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise